Ballentine Partners LLC Makes New $239,000 Investment in argenx SE (NASDAQ:ARGX)

Ballentine Partners LLC purchased a new position in shares of argenx SE (NASDAQ:ARGX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 441 shares of the company’s stock, valued at approximately $239,000.

A number of other large investors have also recently bought and sold shares of the company. J.Safra Asset Management Corp grew its stake in shares of argenx by 590.0% in the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after buying an additional 59 shares in the last quarter. Blue Trust Inc. grew its stake in shares of argenx by 620.0% in the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after buying an additional 62 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in shares of argenx in the second quarter valued at $76,000. Finally, Toronto Dominion Bank grew its stake in shares of argenx by 16.5% in the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after buying an additional 43 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Stock Performance

Shares of NASDAQ ARGX opened at $552.88 on Wednesday. argenx SE has a 52 week low of $327.73 and a 52 week high of $571.97. The stock has a market capitalization of $32.86 billion, a P/E ratio of -97.68 and a beta of 0.63. The stock’s fifty day moving average is $536.03 and its 200 day moving average is $462.82.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ARGX shares. Guggenheim reissued a “buy” rating and issued a $585.00 target price on shares of argenx in a research note on Thursday, September 26th. Evercore ISI raised their price target on argenx from $478.00 to $533.00 and gave the company an “outperform” rating in a report on Friday, July 12th. JPMorgan Chase & Co. raised their price target on argenx from $500.00 to $640.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. Truist Financial raised their price target on argenx from $480.00 to $540.00 and gave the company a “buy” rating in a report on Monday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft downgraded argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $550.44.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.